| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
|
24,949 |
19,297 |
$1.21M |
| 99213 |
|
25,437 |
18,682 |
$919K |
| 90832 |
|
3,467 |
2,462 |
$112K |
| G0467 |
Federally qualified health center (fqhc) visit, established patient; a medically-necessary, face-to-face encounter (one-on-one) between an established patient and a fqhc practitioner during which time one or more fqhc services are rendered and includes a typical bundle of medicare-covered services that would be furnished per diem to a patient receiving a fqhc visit |
2,554 |
2,156 |
$74K |
| 90834 |
|
702 |
520 |
$34K |
| 99215 |
Prolong outpt/office vis |
265 |
180 |
$18K |
| 90674 |
|
908 |
715 |
$14K |
| 36415 |
|
8,754 |
6,845 |
$13K |
| 99000 |
|
13,657 |
10,127 |
$12K |
| 99441 |
|
481 |
421 |
$10K |
| 87804 |
|
1,071 |
762 |
$7K |
| 83036 |
|
1,534 |
1,145 |
$7K |
| 99442 |
|
208 |
155 |
$6K |
| 87811 |
|
248 |
220 |
$5K |
| G0481 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed |
656 |
286 |
$4K |
| 99212 |
|
237 |
168 |
$4K |
| 87880 |
|
506 |
374 |
$3K |
| 90837 |
|
113 |
37 |
$2K |
| 90661 |
|
111 |
109 |
$1K |
| 81003 |
|
582 |
439 |
$786.37 |
| 90756 |
|
51 |
37 |
$752.00 |
| 80305 |
|
206 |
119 |
$711.57 |
| J2930 |
Injection, methylprednisolone sodium succinate, up to 125 mg |
91 |
73 |
$361.30 |
| 99203 |
|
13 |
12 |
$259.77 |
| 3008F |
|
6,683 |
5,032 |
$225.00 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
92 |
79 |
$141.94 |
| 2000F |
|
6,642 |
4,912 |
$100.00 |
| 87426 |
|
20 |
12 |
$93.27 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
38 |
26 |
$59.83 |
| G0071 |
Payment for communication technology-based services for 5 minutes or more of a virtual (non-face-to-face) communication between an rural health clinic (rhc) or federally qualified health center (fqhc) practitioner and rhc or fqhc patient, or 5 minutes or more of remote evaluation of recorded video and/or images by an rhc or fqhc practitioner, occurring in lieu of an office visit; rhc or fqhc only |
12 |
12 |
$54.78 |
| G8427 |
Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications |
334 |
255 |
$11.80 |
| G8752 |
Most recent systolic blood pressure < 140 mmhg |
214 |
164 |
$10.65 |
| G8754 |
Most recent diastolic blood pressure < 90 mmhg |
223 |
171 |
$9.85 |
| 99406 |
|
28 |
25 |
$0.12 |
| 1000F |
|
34 |
28 |
$0.00 |
| G8431 |
Screening for depression is documented as being positive and a follow-up plan is documented |
298 |
240 |
$0.00 |
| 3725F |
|
34 |
26 |
$0.00 |
| G8417 |
Bmi is documented above normal parameters and a follow-up plan is documented |
17 |
13 |
$0.00 |